Le Lézard
Classified in: Health
Subjects: SVY, TDS, ASI

The Evolution Of Clinical Research In East Asia


NEW YORK, June 9, 2015 /PRNewswire/ -- Citeline®, an Informa business unit, and the pharmaceutical industry's leading research authority on clinical trials, reported today that clinical trials in East Asia have increased dramatically over a recent 10 year period, driven primarily by local studies conducted by a single sponsor.

The findings were presented today at the Pharma CI Conference & Exhibition Asia in Tokyo Japan, an event attended by top competitive intelligence professionals in the Japanese pharmaceutical industry. The full report, written by Doro Shin, a well published Citeline analyst, is now publically available.

For her analysis, Ms. Shin used Citeline's Trialtrove® and Trialpredict®, competitive intelligence resources that draw data from over 30,000 sources. The report focuses on Phase I-III industry sponsored trials located in China, Hong Kong, Japan, South Korea and/or Taiwan that were initiated or planned in 2002-2012. While Japan leads the group, as expected, with the largest number of trials, there is a clear rise in the number of trials located in China and South Korea and drop in Hong Kong.

The analysis reveals that 65% of all these trials took place in a single East Asian country, with a high of 78% of Japan's initiated studies involving only local sites compared to 55% in China. In other countries such as South Korea, the majority of trials initiated were part of a larger multinational study.

Phase 1 activity appears to be increasing while the number of Phase III trials remains steady. The most common therapeutic area is oncology, however the top indications for initiated and planned trials are not limited to cancer.

"When looking at who is conducting the trials, there is a very diverse set of players," commented Ms. Shin, "Large multinational companies such as Novartis and Roche, and local headquartered companies such as Takeda and Otsuka, initiated hundreds of their own trials, however overall there were 617 different companies with an average of only 16 trials each. And for this part of the globe, a surprisingly small number of trials involved collaborations between sponsors."

The full report also covers the indications being studied and enrollment trends by phase, location and disease as well as a detailed look into characteristics of new trials currently being planned in East Asia.

The report published today reflects Citeline's continuing efforts to bring relevant analysis to the industry through thought leadership.

To view the full analysis please download the free report ? The Evolution of Clinical Research in East Asia.         

About Citeline

Citeline delivers the pharmaceutical industry's most robust, reliable, and relevant R&D intelligence?all with direct, unlimited analyst support. Citeline's suite of fully integrated solutions features an unmatched data collection of global clinical trials, drug development pipelines, investigators and site profiles. Citeline data is drawn from over 30,000 unique sources and updated in real-time by the industry's largest team of expert analysts and editors.

Contact for Further Information
Julie McKenna
Product Marketing Manager
Citeline Inc.
617-415-1981
julie.mckenna@citeline.com
www.citeline.com

SOURCE Citeline


These press releases may also interest you

at 19:04
Growing initiatives to increase EHR adoption and big data in healthcare are expected to drive the overall growth of the healthcare analytics market.Read the full report: https://www.reportlinker.com/p05222516 The healthcare business analytics market...

at 18:45
Taiho Oncology, Inc. and Servier announced today that the safety and efficacy in patients with gastrectomy from the global Phase 3 TAGS trial evaluating LONSURF® in patients with previously treated metastatic gastric cancer (mGC) are consistent with...

at 18:30
The "Healthcare CRM - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering. Global Healthcare CRM market accounted for $7.27 billion in 2017 and is expected to reach $28.89 billion by 2026 growing at a CAGR...

at 18:25
Muhammad Yasser Darkazally, M.D. is recognized by Continental Who's Who as a Pinnacle Lifetime Member in the field of Internal Medicine in recognition of his role as an Internist at Saint Francis Hospitalists.        Established in 1960, Saint...

at 17:45
The "Microcrystalline cellulose - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering. Global Microcrystalline cellulose market accounted for $829.50 million in 2017 and is expected to reach $1,652.19 million...

at 17:30
It's going to be a great night! Arthritis Research Canada is a world leader in finding answers and saving lives for the over 6 million Canadians affected by arthritis. Join us for the 7th annual ARThritis Soirée - May 22, 2019 at The Roof, Hotel...



News published on 9 june 2015 at 14:15 and distributed by: